Vasopressin receptor subtype(s) responsible for stimulation of insulin release from pancreatic ␤ cells were investigated by using subtype-selective antagonists and mice that were genetically lacking either V1a or V1b receptors. Arginine vasopressin (AVP) increased insulin release from isolated mouse islet cells in a concentration-dependent manner, with a submaximal response at 100 nM. Reverse transcription-polymerase chain reaction (RT-PCR) analysis detected V1b and oxytocin, but not V1a or V2, receptor transcripts in mouse islet cells. We characterized the recently synthesized vasopressin receptor subtype antagonists
cells stably expressing the three cloned mouse vasopressin receptors (V1a, V1b, and V2). A radioligand binding study showed that SR49059 and OPC-21268 potently inhibited [ 3 H]AVP binding to the cloned mouse V1a receptor, with K i values of 27 and 510 nM, respectively, whereas SSR149415 potently inhibited [ 3 H]AVP binding to the cloned mouse V1b receptor with a K i value of 110 nM. The inhibitory effects of vasopressin antagonists on AVP-induced insulin release correlate well with the rank order of potency to inhibit [ 3 H]AVP binding to the V1b receptor; pancreatic islet cells were significantly inhibited by SSR149415 but not by SR49059 or OPC-21268. Furthermore, the AVP effect on insulin release was entirely lost in mice lacking the V1b receptor but was preserved in mice lacking the V1a receptor. Our study, which combined pharmacological and knockout approaches, clearly demonstrates that vasopressin-stimulated insulin release from islet cells is mediated via V1b receptors.
The neurohypophysial hormone arginine vasopressin (AVP), and related peptides, including oxytocin (OT), exert their effects through at least four types of G protein-coupled receptors, termed V1a, V1b, V2, and OT receptors (Birnbaumer, 2000; Thibonnier et al., 2001) . Among the plethora of physiological processes regulated by AVP (Morel et al., 1992; Thibonnier et al., 2001 ) is the homeostatic control of blood glucose levels. AVP can decrease the blood glucose level by promoting insulin release, and it can also increase the blood glucose level by promoting the release of glucagon (Dunning et al., 1984b; Chen et al., 1994; Yibchok-Anun and Hsu, 1998) and by enhancing glycogenolysis in the liver (Kirk et al., 1979) . The AVP-induced hepatic glycogenolysis is mediated predominantly by the V1a receptor subtype (Morel et al., 1992) , whereas the specific receptor responsible for the AVP-promoted insulin release from the pancreas is still unclear. An immunohistological study showed the presence of AVP in the human and rat pancreas, and AVP may work as an important local modulator of pancreatic hormone secre-tion (Amico et al., 1988; Folny et al., 2003) . In addition, it has been shown that stimulation of vasopressin receptors in the pancreatic islet cells leads to stimulation of phospholipase C, resulting in the formation of inositol 1,4,5-trisphosphate and diacylglycerol (Gao et al., 1990) .
Pharmacological studies have been performed to determine the vasopressin receptor subtype that is responsible for insulin secretion (Dunning et al., 1984a; Monaco et al., 1988) . The application of V1b receptor agonist desamino(D-3-(3Ј-pyridyl)-Ala 2 ,Arg 8 )VP was reported to increase insulin release from hamster ␤ cells (Richardson et al., 1995) . In addition, it was reported that receptor blockade by a mixed V1a/b antagonist, but not by a V1a antagonist, reduced AVP-stimulated insulin release (Lee et al., 1995; Richardson et al., 1995) . Because of the lack of a sufficiently specific V1b-blocker, however, definitive conclusions based on these studies have remained elusive (Gao and Henquin, 1993) . Recently, highly selective peptide and nonpeptide vasopressin receptor antagonists have been developed (Hirasawa et al., 1994; Thibonnier et al., 2001) . Nonpeptide V1a receptorselective antagonists such as OPC21268 and SR49059 have been developed for potential therapeutic use in treating hypertension and congestive heart failure (Yamamura et al., 1991; Serradeil-Le Gal et al., 1993) . More recently, a V1b receptor-selective antagonist, SSR149415, has been developed. Pharmacological studies showed that it inhibits the exogenous AVP-induced increase in circulating corticotropin and produces anxiolytic-and antidepressant-like effects (Griebel et al., 2002; Serradeil-Le Gal et al., 2002a,b) .
In addition to these pharmacological characterizations, V1a and V1b receptor knockout (KO) mice have been generated successfully by our group as well as by another group (Wersinger et al., 2002; Tanoue et al., 2004 ; A. Tanoue, Y. Nasa, R. Oikawa, Y. Kawahara, S. Oshikawa, Y. Kitagawa, T. Koshimizu, N. Hatae, T. Kuwaki, S. Takeo, and G. Tsujimoto, submitted for publication). V1a-and V1b-KO mutations are not lethal and the mice have no apparent anatomical anomaly. The V1a and V1b receptor-mediated AVP responses were completely lost in V1a-KO and V1b-KO, respectively; thus, AVP-stimulated pressor response and corticotropin release were completely lost in V1a-KO and V1b-KO, respectively. These results indicated that both the V1a and V1b receptors were indispensable for these effects, and deleting these receptor genes apparently did not trigger any compensatory mechanism (Wersinger et al., 2002; Tanoue et al., 2004 ; A. Tanoue, Y. Nasa, R. Oikawa, Y. Kawahara, S. Oshikawa, Y. Kitagawa, T. Koshimizu, N. Hatae, T. Kuwaki, S. Takeo, and G. Tsujimoto, submitted for publication). Hence, these KO mice are good animal models to study the physiology of each receptor subtype.
In the present study, we investigated vasopressin receptor subtype(s) responsible for AVP-induced insulin release from pancreatic cells. This was done pharmacologically, using subtype-selective antagonists, and by using mice that genetically lacked either the V1a or the V1b receptor. Animals. Mice deficient in V1a or V1b receptors were generated by gene targeting as described elsewhere (Tanoue et al., 2004 ; A. Tanoue, Y. Nasa, R. Oikawa, Y. Kawahara, S. Oshikawa, Y. Kitagawa, T. Koshimizu, N. Hatae, T. Kuwaki, S. Takeo, and G. Tsujimoto, submitted for publication). Corresponding wild-type mice (12 weeks of age) were used as control mice. Mice were maintained under controlled condition at 25°C, with food and water available ad libitum. All animal experiments described were approved and conducted in accord with our institutional standards of animal care.
Materials and Methods

Materials
Isolation of cDNA for Mouse Vasopressin Receptors. cDNAs of the mouse V1a, V1b, and V2 receptors were obtained by the RT-PCR method. Total RNAs from the mouse liver, pituitary, and kidney were prepared using Isogen reagent (Nippon Gene, Tokyo, Japan). Total RNA (5 g) was treated with RNase-free DNase (Takara, Tokyo, Japan) and reverse-transcribed using random hexamers, as described previously (Tanoue et al., 1990) . One tenth of each cDNA sample was amplified by PCR with receptor-specific primers (10 pmol of each) in a buffer containing 0.25 mM of each dNTP, 50 mM KCl, 10 mM Tris-HCl, pH 8.6, 1.5 mM MgCl 2 , and 2.5 units of Taq DNA polymerase (Takara, Tokyo, Japan). Thermal cycling was performed for 1 min at 94°C, 1 min at 56°C, and 2 min at 72°C for 30 cycles. The upstream and downstream primers (5Ј33Ј) were AATGAATTCATGAGTTTCCCGCGAGGC and TCCGGATCCAGTGGAGACAGGGTAAA for V1a (1672 bp), CAA-GAATTCATGGATTCTGAGCCTTCT and AACGGATCCAGAGAT-GCTGGTCTCCAT for V1b (1574 bp), and ATGATCCTGGTGTC-TACCAC and TAGAAAGAGCCCAGTAGCTAC for V2 (1137 bp). The primers were derived from the mouse V1a and V1b genomic sequences (Kikuchi et al., 1999 ) (GenBank accession numbers are AB030013 and SEG AB030448S for V1a and V1b, respectively) and primers for V2 were from a previous report (Oksche et al., 2002) (GenBank accession number is NM 019404). The amplified cDNAs were then subcloned into pGEM-vectors and sequenced.
RT-PCR Analysis. Our preliminary Northern blot analysis revealed that the expression level of the V1b receptor transcript was very restricted and that this mRNA was scarce. Therefore, studies on its tissue distribution were performed by RT-PCR. cDNA samples from different mouse tissues were amplified by PCR with primer sets specific to the receptors or to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The upstream and downstream primer sequences, located within the first exon of the mouse V1a, V1b, V2, and OXT genes, were ATTGCTGGGCTAC-CTTCATCC upstream and CCTTGGCGAATTTCTGCGCT downstream for V1a (532 bp), TCACCTGGACCACCATGGCCAT upstream and CTTCATTAGGGGCATTCTCGT downstream for V1b (333 bp), GACCCCCCTTTGTGTTGCTCA upstream and TCAG-GAGGGTGTATCCTTCAT downstream for V2 (206 bp), and TCAGCTTCAAGATCTGGCAG upstream and TCTACCCACTGC-CCAGGAAC downstream for OXT (771 bp). The GAPDH sequences (5Ј33Ј) were GGTCATCATCTCCGCCCCTTC for sense and CCACCACCCTGTTGCTGTAG for antisense primers (662 bp), respectively. Control PCR reactions were also performed on non-reverse-transcribed RNA to exclude any contamination with genomic DNA.
HEK293 Cells Stably Expressing Mouse V1a, V1b, and V2 Receptors. The mouse V1a, V1b, and V2 cDNAs were subcloned into the mammalian expression vectors pcDNA3.1 and pEGFP-N 3 . HEK293 cells were stably transfected with each of the pEGFP-N 3 624 Oshikawa et al.
constructs using the LipofectAMINE reagent (Invitrogen). Individual colonies of transfected HEK293 cells resistant to G-418 were picked up and selected according to the intensity of their fluorescent signal using an EPICS XL-MCL flow cytometer (Beckman Coulter, Fullerton, CA). As a negative control, HEK293 cells were also stably transfected with the pcDNA3.1. Nucleotide sequences of all these clones were verified using the dye terminator technique, with a model 377 DNA sequencer from Applied Biosystems (Foster City, CA).
Ligand Binding Assay. Cellular membrane fractions were prepared from HEK293 cells that were stably expressing mouse V1a, V1b, or V2, as described previously (Shibata et al., 1995) . Briefly, the collected cells were placed in 2 ml of ice-cold buffer A (250 mM sucrose, 5 mM Tris-HCl, and 1 mM MgCl 2 , pH 7.4), and disrupted in a Branson sonicator (SONIFIER 250; Branson, Danbury, CT) at setting 5 for 8 s. The mixture was then centrifuged at 1000g at 4°C for 10 min to remove nuclei. The supernatant was centrifuged at 35,000g for 20 min at 4°C. The resulting pellet was suspended in binding buffer B (100 mM Tris-HCl, 5 mM MgCl 2 , 1 mM EDTA, and 1 mg/ml BSA, pH 7.4) and was frozen at Ϫ80°C until assay. Protein concentration was measured using the bicinchoninic acid protein assay kit (Pierce, Rockford, IL).
Radioligand binding studies using [ 3 H]AVP were performed as described previously (Hirasawa et al., 1994) . The reaction was initiated by adding the membranes in 250 l of a buffer containing 100 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 , 1 mM EDTA, 1 mg/ml BSA, and [ 3 H]AVP (0.1ϳ10.0 nM), incubated for 30 min at 30°C. The reaction was terminated by addition of 4 ml of ice-cold washing solution (100 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 , 1 mM EDTA, and 0.1 mg/ml BSA), immediately filtered onto Whatman glass fiber (0.8-1.2 m), and binding was measured by liquid scintillation spectrometry. To determine nonspecific binding, 1 M concentrations of unlabeled AVP was used. The specific binding was calculated as the difference between the total and nonspecific counts. (Shibata et al., 1976) . Briefly, after clamping the common bile duct at its entrance to the duodenum, 3 ml of Hanks' medium containing 2 mg/ml of collagenase S-1 (Nitta, Japan) was injected into the duct. The swollen pancreas was surgically removed, incubated at 37°C for 20 min, and digestion was terminated by adding 40 ml of ice-cold RPMI medium containing 10% FBS. Digested pancreata were then dispersed by pipetting and rinsed twice with 30 ml of the same medium. After filtering through a Spectra-mesh (408 m; Spectrum Laboratories, Inc., Ft. Lauderdale, FL), the digested tissue was resuspended in a 4-ml layer of Ficoll (specific gravity, 1.22) and overlaid with a 2-ml layer of Ficoll, with specific gravities of 1.09 and 1.05, respectively. The sample was then centrifuged at 2000g for 10 min, and the islets were collected from the interface. The recovered material was washed twice with ice-cold Hanks' medium, resuspended in RPMI medium containing 10% FBS, and cultured overnight at 37°C in 5% CO 2 . Because extracellular glucose level needs to be set above 7 mM to detect AVP actions (Gao et al., 1990) , we cultured primary islet cells in an assay solution containing 11 mM glucose. Islets were stimulated with 0.1 M AVP for 20 min at 37°C. The incubation was terminated by brief centrifugation at 1000g. Supernatants were collected and assayed for insulin content by an ELISA method (Mercodia, Sweden).
Measurement of Blood Glucose. After a 16-h fast, tail blood samples were taken and glucose level was measured using a blood glucose meter (Ascencia; Bayer Japan Ltd., Japan).
Data Analysis. The radioligand binding data were analyzed by the iterative nonlinear regression program, LIGAND (Munson and Rodbard, 1980) . The dissociation constant (K D ) and the maximal binding capacity (B max ) were deduced from Scatchard plotting. The inhibitory dissociation constants (K i ) for unlabeled AVP analogs were calculated from competition binding experiments according to Cheng and Prusoff, using the following equation (Cheng and Prusoff, 1973) :
, where IC 50 is the concentration of unlabeled antagonist leading to half-maximal inhibition of specific binding and [L] is the concentration of the radioligand present in the assay. Experiments were repeated at least three times and data were expressed as mean Ϯ S.E. Statistical analysis was performed with the Statview software package (Abacus Concepts Inc., Berkeley, CA). Significant differences with P Ͻ 0.05 were determined by the oneway analysis of variance with Newman-Keuls multiple comparison test.
Results and Discussion
mRNA Expression of AVP Receptors in Mouse Islet
Cells. Expression of the AVP receptor mRNA in various mouse tissues was first examined by RT-PCR. As shown in Fig. 1A , both V1a and V2 receptor mRNA were widely detected in brain and other peripheral tissues, including mesenteric artery, heart, lung, liver, pancreas, spleen, kidney, and adrenal grand. In contrast, the V1b receptor had a limited tissue distribution. It was initially defined as a pituitaryspecific subtype in rat and human (Jard et al., 1986; Lolait et al., 1995; Grazzini et al., 1996; Hurbin et al., 1998; Vaccari et al., 1998) ; indeed, its mRNA was markedly abundant in pituitary glands. A faint but positive signal for the V1b receptor subtype was consistently detected in brain and adrenal gland.
In cDNA samples prepared from whole pancreas tissue, the transcripts for the V1a and V2 receptors were barely detectable, whereas the V1b receptor was not detected (Fig. 1A) . However, when total RNA was extracted from isolated islet cells, the transcripts for V1b and OT receptors were clearly detected (Fig. 1B) ) was 8.9 Ϯ 0.1 (n ϭ 6), 0.3 Ϯ 0.01 (n ϭ 3), and 1.0 Ϯ 0.01 (n ϭ 3) pmol/mg protein in cell lines expressing V1a, V1b, and V2 receptor, respectively.
Scatchard plot analysis showed a single class of high-affinity binding site in each stable cell line, with K D values of 1.3 Ϯ 0.1 (n ϭ 6), 0.3 Ϯ 0.1 (n ϭ 5), and 0.3 Ϯ 0.1 (n ϭ 3) nM for the V1a, V1b, and V2 receptors, respectively. As shown in Fig. 2 and in mice and that SR49059 was a V1a antagonist with ϳ20 times more selective for the V1a receptor over V1b receptor. SSR149415 exhibited a higher affinity for the mouse V1b receptor (pK i ϭ Ϫ7.0 Ϯ 0.2, n ϭ 4) than the V1a (pK i ϭ Ϫ5.2 Ϯ 0.6, n ϭ 4) and V2 (pK i ϭ Ϫ5.2 Ϯ 0.5, n ϭ 4) receptors, indicating that SSR149415 is useful for identifying the V1b-mediated effects in mice. Affinity of OPC-21268 for the mouse V1a receptor was 100 times higher than its affinity for V1b and V2 receptors, whereas OPC-31260 was selective for the V2 subtype.
The new V1b receptor antagonist, SSR149415, has been reported to show high affinity for both human and rat V1b receptors; K i values are 1.5 and 1.3 nM for human and rat V1b receptors, respectively (Serradeil-Le Gal et al., 2002a) . However, we found that K i value of SSR149415 for mouse V1b receptor was approximately 80-fold larger compared with those observed for human and rat V1b receptors, although SSR149415 still displayed more than 50-fold higher affinity for the V1b receptor than for other vasopressin and oxytocin receptors in mice. In addition, we found that [Pmp 1 ,Tyr (Me)   2 ]-Arg 8 -vasopressin was nonselective for three vasopressin receptor subtypes in mice, although it had been reported to be selective for V1a receptor in rat (Kruszynski et al., 1980; Morel et al., 1992; Lolait et al., 1995) . A similar species-dependent difference in the binding properties at vasopressin receptor has been noted for synthetic vasopressin receptor ligand OPC-21268; thus, the rat V1a receptor exhibited more than 1000 times higher affinity than the human homolog (Hirasawa et al., 1994) .
Effects of Receptor Antagonists on AVP-Induced Insulin Release from Mouse Islet Cells. AVP caused a significant, concentration-dependent increase in insulin release from mouse islets in the agonist dose range from 1 to 100 nM, and the dose of 100 nM AVP was used for a further series of experiments to examine the effects of antagonists. As shown in Fig. 3, a ]-Arg 8 -vasopressin, inhibited AVP-induced insulin release in a concentration-dependent manner in a range from 10 to 1000 nM (Fig. 3) . However, SR49059 weakly antagonized insulin release at high concentrations (over 1 M), and the V1a receptor antagonist, OPC-21268, was inef- fective even at 1 M. In contrast, V1b-selective SSR149415 potently inhibited the AVP action even at 1 nM (n ϭ 6), and this inhibitory effect was concentration-dependent. At all concentrations tested, application of the antagonists without AVP did not change insulin release (data not shown). Hence, the V1b receptor affinity for the antagonist correlates well with its efficiency in inhibiting AVP-induced insulin release from islet cells. AVP-Induced Insulin Release from Islet Cells in V1a-and V1b-KO Mice. We further examined the consequence of deleting individual V1 receptor genes in AVP-induced insulin release. V1a and V1b receptor transcripts were absent in the islets from V1a-KO and V1b-KO, respectively (Fig. 4A) . AVPinduced accumulation of insulin release from cultured islet cells was similar for the V1a-KO and wild-type control mouse. However, AVP-stimulated insulin release from the islet cells was completely lost in V1b-KO mice (Fig. 4B) . This is in good agreement with the results obtained from pharmacological characterization. Both studies show that the V1b receptor subtype is fully operative in mouse pancreatic islet cells and that AVP-mediated insulin release seems to occur solely via the V1b receptor. When a fasting blood glucose level was obtained from control and V1b-KO mice, no significant difference was observed between two groups: 57 Ϯ 2 mg/dL for control mice (n ϭ 12) and 52 Ϯ 3 mg/dL for V1b-KO mice (n ϭ 10), respectively.
Glucose stimulates an increase in the intracellular Ca 2ϩ concentration in pancreatic ␤ cells and causes the insulin secretion. This process can be mainly regulated by plasma membrane depolarization as well as by the CD38-cyclic ADP ribose signal system (Okamoto and Takasawa, 2002) . Vasopressin can work as a positive modulator for the glucosestimulated insulin release by acting on both signal cascades. Upon the stimulation of the ␤ cells by AVP, intervals between rhythmic plasma membrane depolarization were significantly shortened, suggesting that a continuously depolarizing current could be generated by AVP (Gao et al., 1990) . In addition, AVP was previously reported to facilitate closing ATP-sensitive potassium channel, a critical regulator of the plasma membrane potential (Cook and Hales, 1984) , in an insulin-secreting RINm5F cells (Martin et al., 1989) . In addition to the ATP-sensitive potassium channel, voltage-dependent calcium channels as well as voltage-independent capacitative channels are known to be operative in pancre- atic ␤-cells (Miura et al., 1997) . Hence, activation of vasopressin V1b receptor may lead to mobilization of the intracellular calcium and depletion of the store and thereby cause a capacitative current that facilitates the voltage-dependent calcium influx (Miura et al., 1997) . Furthermore, stimulation of the V1b receptor activates phospholipase C pathway and downstream signaling molecules, such as protein kinase C (Birnbaumer, 2000; Thibonnier et al., 2001 ). V1b receptor can promote insulin exocytosis by activating protein kinase C, because another member of G protein-coupled receptors, m3 muscarinic receptor, was shown to facilitate insulin exocytosis by activating this kinase (Gilon and Henquin, 2001) . Moreover, V1b receptor-mediated signal may have a crosstalk with the CD38-cyclic ADP ribose signal system. V1b knockout mouse would provide a valuable model system for further studying the molecular mechanism for the AVP action to promote glucose-stimulated insulin secretion in pancreas ␤-cells.
Although OT receptor transcripts were also found in islets by the RT-PCR analysis, a previous study demonstrated that the OT receptor antagonist had no effect on AVP-induced insulin release in perifused rat pancreas (Lee et al., 1995) . In addition, SSR149415 is more than 100 times more selective for V1b over OT receptors (Serradeil-Le Gal et al., 2002a) , and AVP-induced insulin secretion was totally blunted in the V1b-KO mice. Taken together, our results indicate that the possible role of the OT receptor in insulin release was not detectable and that the V1b receptor is a major mediator of AVP action in mouse ␤ cells.
In conclusion, we provide here the first direct illustration that blunting of V1b signaling in pancreatic ␤ cells resulted in refractoriness to AVP stimulation. By using V1b receptor antagonists, developmental changes resulting from ablation of the V1b gene and acute effects of receptor blockade can be distinguished. Our approach of combining pharmacological and knockout techniques clearly demonstrates that vasopressin-stimulated insulin release from islet cells is mediated via V1b receptors.
